Form 10-K Trovagene, Inc. For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Trovagene (TROV) Misses Q4 EPS by 1c
March 10, 2016 4:23 PM ESTTrovagene (NASDAQ: TROV) reported Q4 EPS of ($0.26), $0.01 worse than the analyst estimate of ($0.25).
2016 Goals and Objectives
Continue to build clinical evidence supporting the use of Trovagene's PCM platformSubmit 8 or more abstracts for presentation at key medical meetings in... More